A clinical assessment of locabiotal in the treatment of infections of the nose and throat.
One hundred and twenty patients suffering from diseases of the nose and throat were admitted to an open clinical trial of the aerosol inhaler Locabiotal which contains the antibiotic fusafungine. The patient population was derived from three sources--out-patients, patients subjected to surgery and emergencies. The aerosol was administered five times daily to the throat or into the nose. The aerosol was highly effective in controlling infection and in relieving the various symptoms of the diseases treated. Variation in particle size was considered to be an advantage in penetrating various parts of the upper respiratory tract. Thirty-three patients experienced minor side-effects. These were thought to be misuse of the inhaler, or possible allergy to the antibiotic. This form of medication is recommended for a variety of diseases of the nose and throat.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D047630:Depsipeptides; D006801:Humans; D008875:Middle Aged; D009668:Nose Diseases / Q000188:drug therapy*; D010608:Pharyngeal Diseases / Q000188:drug therapy*; D013997:Time Factors
D000336:Aerosols; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; C014001:fusafungin